Lessons from sickle cell disease in the treatment and control of malaria

New England Journal of Medicine

Volumn 364, Issue 26, 2011, Pages 2549-2551

  Rosenthal, Philip J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTESUNATE; BETA GLOBIN; HEMOGLOBIN A; HEMOGLOBIN S; INSECTICIDE; MALARIA VACCINE;

ARTICLE; BRAIN MALARIA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; GENE MUTATION; GENOTYPE; HUMAN; IMMUNOLOGICAL TOLERANCE; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SYMPTOM; TREATMENT RESPONSE;

EID: 79959783522     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr1105118     Document Type: Article

References (5)

1. Williams TN. Human red blood cell polymorphisms and malaria. Curr Opin Microbiol 2006;9:388-94. (Pubitemid 44108720)
2. Ferreira A, Marguti I, Bechmann I, et al. Sickle hemoglobin confers tolerance to Plasmodium infection. Cell 2011;145:398-409.
3. de Souza JB, Hafalla JC, Riley EM, Couper KN. Cerebral malaria: why experimental murine models are required to understand the pathogenesis of disease. Parasitology 2010;137:755-72.
4. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010;376:1647-57.
5. Roestenberg M, McCall M, Hopman J, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009;361:468-77.